Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial

This study provides Class II evidence that masitinib 4.5 mg/kg/d decreased progression of disability, measured by the EDSS, in adults with PPMS or patients with nSPMS (with no exacerbations in the last 2 years).

Source: Neurology Neuroimmunology and Neuroinflammation - February 21, 2022 Category: Neurology Authors: Vermersch, P., Brieva-Ruiz, L., Fox, R. J., Paul, F., Ramio-Torrenta, L., Schwab, M., Moussy, A., Mansfield, C., Hermine, O., Maciejowski, M., on behalf of the AB07002 Study Group, on behalf of the AB07002 Study Group Tags: Clinical trials Randomized controlled (CONSORT agreement), Class II, Multiple sclerosis Article Source Type: research